Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Ligachem Biosciences signed a joint research and license agreement with South Korea’s Abion on Sept. 30, 2026 to develop iADC candidates. Ligachem has worldwide exclusive rights across up to five targets it selects; financial terms were not disclosed.
Abion entered a joint research and licensing deal with LigaChem Biosciences to co-develop an iADC drug candidate, using Abion’s IFN-β mutein immunocytokine-antibody and LigaChem’s proprietary ADC platform; LigaChem has exclusive rights and can designate up to five targets. Contract signed Sept. 30, 2026; financial term